TY - JOUR
T1 - Long-term endoscopic remission in Crohn’s disease after allogeneic hematopoietic stem cell transplantation for diffuse large B cell lymphoma
T2 - case report and literature review
AU - Inomata, Yushi
AU - Kuroha, Masatake
AU - Handa, Tomoyuki
AU - Shimoyama, Yusuke
AU - Moroi, Rintaro
AU - Shiga, Hisashi
AU - Kakuta, Yoichi
AU - Ichikawa, Satoshi
AU - Fukuhara, Noriko
AU - Sato, Yuichiro
AU - Takahashi, Taro
AU - Masamune, Atsushi
N1 - Funding Information:
We would like to thank Dr. Izuru Abe, Dr. Kota Yano, Dr. Fumiko Shimoda, and Dr. Takahiro Takahashi for their assistance in this study.
Publisher Copyright:
© 2021, Japanese Society of Gastroenterology.
PY - 2021/8
Y1 - 2021/8
N2 - A 31-year-old man with Crohn’s disease in remission after 6-year treatment with infliximab developed nasopharyngeal diffuse large B cell lymphoma. Infliximab was discontinued, and complete remission was achieved following chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. However, the patient subsequently experienced severely symptomatic Crohn’s disease relapse. Therapy with adalimumab was initiated, and the patient attained remission. However, after 3 months, he suffered a recurrence of the lymphoma. Adalimumab was discontinued, and the patient received further chemotherapy (with rituximab, etoposide, cisplatin, methylprednisolone, and high-dose cytarabine) treatment and underwent allogeneic hematopoietic stem cell transplantation. Following the procedure, Crohn’s disease and lymphoma have remained in complete remission for 5 years. There are limited reports on Crohn’s disease remission after allogeneic hematopoietic stem cell transplantation. Therefore, we present this case report and a review of the existing literature on allogeneic stem cell transplantation for Crohn’s disease.
AB - A 31-year-old man with Crohn’s disease in remission after 6-year treatment with infliximab developed nasopharyngeal diffuse large B cell lymphoma. Infliximab was discontinued, and complete remission was achieved following chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. However, the patient subsequently experienced severely symptomatic Crohn’s disease relapse. Therapy with adalimumab was initiated, and the patient attained remission. However, after 3 months, he suffered a recurrence of the lymphoma. Adalimumab was discontinued, and the patient received further chemotherapy (with rituximab, etoposide, cisplatin, methylprednisolone, and high-dose cytarabine) treatment and underwent allogeneic hematopoietic stem cell transplantation. Following the procedure, Crohn’s disease and lymphoma have remained in complete remission for 5 years. There are limited reports on Crohn’s disease remission after allogeneic hematopoietic stem cell transplantation. Therefore, we present this case report and a review of the existing literature on allogeneic stem cell transplantation for Crohn’s disease.
KW - Adalimumab
KW - ASTIC trial
KW - Autologous hematopoietic stem cell transplantation
KW - Infliximab
KW - Umbilical cord blood transplantation
UR - http://www.scopus.com/inward/record.url?scp=85103400308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103400308&partnerID=8YFLogxK
U2 - 10.1007/s12328-021-01389-4
DO - 10.1007/s12328-021-01389-4
M3 - Article
C2 - 33786703
AN - SCOPUS:85103400308
SN - 1865-7257
VL - 14
SP - 1108
EP - 1114
JO - Clinical Journal of Gastroenterology
JF - Clinical Journal of Gastroenterology
IS - 4
ER -